The DOI matches its Crossref record; 185 of the 185 references it cites were found in a registry or an index.
Neuroprotection in Glaucoma: Animal Models and Clinical Trials
Open accessAbstract
Glaucoma is a progressive neurodegenerative disease that frequently results in irreversible blindness. Glaucoma causes death of retinal ganglion cells (RGCs) and their axons in the optic nerve, resulting in visual field deficits and eventual loss of visual acuity. Glaucoma is a complex optic neuropathy, and a successful strategy for its treatment requires not only better management of known risk factors such as elevated intraocular pressure and the development of improved tools for detecting RGC injury but also treatments that address this injury (i.e., neuroprotection). Experimental models of glaucoma provide insight into the cellular and molecular mechanisms of glaucomatous optic neuropathy and aid the development of neuroprotective therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“To our knowledge, this is the first example of vision loss reversal after glaucomatous injury has occurred, with previous attempts focusing on neuroprotection delivered at an early stage to prevent further disease progression41,42 (Supplementary discussion).”
From Reprogramming to recover youthful epigenetic information and restore vision (2020) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
The Ocular Hypertension Treatment Study
Kass, M. A. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.6.701 · Cited by 3,736
Phototransduction by retinal ganglion cells that set the circadian clock
Berson, D. M., Dunn, F. A., & Takao, M. (2002) · Science · doi:10.1126/science.1067262 · Cited by 3,629
Reduction of Intraocular Pressure and Glaucoma Progression
Heijl, A. (2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.10.1268 · Cited by 3,407
Song, S.-K., Sun, S.-W., Ju, W.-K., Lin, S.-J., Cross, A. H., & Neufeld, A. H. (2003) · NeuroImage · doi:10.1016/j.neuroimage.2003.07.005 · Cited by 1,738
Update of the Stroke Therapy Academic Industry Roundtable Preclinical Recommendations
Fisher, M., Feuerstein, G., Howells, D. W., Hurn, P. D., Kent, T. A., Savitz, S. I., & Lo, E. H. (2009) · Stroke · doi:10.1161/strokeaha.108.541128 · Cited by 1,352
A Novel Human Opsin in the Inner Retina
Provencio, I., Rodriguez, I. R., Jiang, G., Hayes, W. P., Moreira, E. F., & Rollag, M. D. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00600.2000 · Cited by 1,290
Parallel processing in the mammalian retina
Wässle, H. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1497 · Cited by 1,253
Research works printed but not linked: 15
- Binley KE, 2016, Eur. J. Neurosci., 44, 2028
- Cioffi GA, 2005, Trans. Am. Ophthalmol. Soc., 103, 592
- Harwerth RS, 1999, Investig. Ophthalmol. Vis. Sci., 40, 2242
- Jia L, 2000, Investig. Ophthalmol. Vis. Sci., 41, 3415
- John SW, 1998, Investig. Ophthalmol. Vis. Sci., 39, 951
- Johnson EC, 2000, Investig. Ophthalmol. Vis. Sci., 41, 431
- Kimura A, 2017, Histol. Histopathol., 32, 215
- Levin LA, 2008, Am. J. Manag. Care, 14, S11
- Levkovitch-Verbin H, 2002, Investig. Ophthalmol. Vis. Sci., 43, 402
- May CA, 2002, Investig. Ophthalmol. Vis. Sci., 43, 2206
- Mozaffarieh M, 2008, Mol. Vis., 14, 224
- Reinstein S, 2009, Compendium, 31, 450
- Wall M, 1997, Investig. Ophthalmol. Vis. Sci., 38, 426
- WoldeMussie E, 2001, Investig. Ophthalmol. Vis. Sci., 42, 2849
- Yoles E, 1999, Investig. Ophthalmol. Vis. Sci., 40, 65
Cited by
Sorted by citations
Reprogramming to recover youthful epigenetic information and restore vision
Lu, Y., Brommer, B., Tian, X., Krishnan, A., Meer, M., Wang, C., Vera, D. L., Zeng, Q., Yu, D., Bonkowski, M. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2975-4 · Cited by 820
“To our knowledge, this is the first example of vision loss reversal after glaucomatous injury has occurred, with previous attempts focusing on neuroprotection delivered at an early stage to prevent further disease progression 41,42 (Supplementary discussion).”
Oxidative stress in the eye and its role in the pathophysiology of ocular diseases
Böhm, E. W., Buonfiglio, F., Voigt, A. M., Bachmann, P., Safi, T., Pfeiffer, N., & Gericke, A. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102967 · Cited by 334
Neurotoxic Reactive Astrocytes Drive Neuronal Death after Retinal Injury
Guttenplan, K. A., Stafford, B. K., El-Danaf, R. N., Adler, D. I., Münch, A. E., Weigel, M. K., Huberman, A. D., & Liddelow, S. A. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107776 · Cited by 221
Preservation of vision after CaMKII-mediated protection of retinal ganglion cells
Guo, X. V., Zhou, J., Starr, C. R., Mohns, E. J., Li, Y., Chen, E. P., Yoon, Y., Kellner, C. P., Tanaka, K., Wang, H., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.031 · Cited by 178
Zhang, N., Wang, J., Chen, B., Li, Y., & Jiang, B. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.624179 · Cited by 169
Metadata
- Authors
- Almasieh, M., & Levin, L. A.
- Affiliations
- Hôpital Maisonneuve-Rosemont (CA)
- University of Wisconsin–Madison (US)
- Corresponding author
- Levin, Leonard A.
- Venue
- Annual Review of Vision Science
- Publisher
- Annual Reviews
- Published
- 2017-09-15
- Volume
- 3
- Issue
- 1
- Pages
- 91-120
- ISSN
- 2374-4642 (ISSN-L)
- 2374-4650
- OpenAlex
- W2732996930
- Cited by
- 111
- References
- 185
- Citations by year
- 2026: 7 · 2025: 10 · 2024: 8 · 2023: 19 · 2022: 19 · 2021: 13 · 2020: 18 · 2019: 12 · 2018: 3 · 2017: 2
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Annual Review of Vision Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Research to Prevent Blindness
- Canada Research Chairs
- National Institutes of Health
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Keywords
- glaucoma, neuroprotection, retinal ganglion cells, optic neuropathy, glaucoma animal model, neuroprotective therapy, intraocular pressure, retinal ganglion cell death, visual field defects
- MeSH terms
- Neuroprotection, Animals, Disease Models, Animal, Glaucoma, Humans, Optic Nerve Diseases, Neuroprotective Agents, Neurodegenerative Diseases, Laser Therapy, Translational Research, Biomedical
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
